Comparison of hormonal activity of isoflavone-containing supplements used to treat menopausal complaints

Menopause

Volumn 16, Issue 5, 2009, Pages 1049-1060

  Reiter, Evelyne ^a,b   Beck, Verena ^a   Medjakovic, Svjetlana ^a,b   Mueller, Monika ^a,b   Jungbauer, Alois ^a,b  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^b INSTITUTE FOR MICROELECTRONICS   (Austria)

Author keywords

Binding affinity; Isoflavones; Red clover; Soy; Transactivation

Indexed keywords

AGLYCONE; ANDROGEN RECEPTOR; BIOCHANIN A; BIOESTRIL; DAIDZEIN; DAIDZIN; EFFIACLIM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROMINERAL; ESTROVONE; EVESTREL; FEMARELLE; FEMIFLAVON FORTE; FITORMIL OMEGA; FORMONONETIN; GENISTEIN; GENISTIN; GLYCITEIN; ISOFLAVONE; MENOFLAVON; MENOFLAVON FORTE; MENOFLAVON OSTEO; MINAPENT; ONONIN; ORTHOMOL FEMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROGESTERONE RECEPTOR; RESVERATROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DIET SUPPLEMENTATION; DRUG RECEPTOR BINDING; HORMONE ACTION; MENOPAUSAL SYNDROME; RED CLOVER;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; DIETARY SUPPLEMENTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FOOD LABELING; GLUCOSIDES; HUMANS; ISOFLAVONES; MENOPAUSE; NUTRITION POLICY; NUTRITIVE VALUE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHYTOTHERAPY; RECEPTORS, ANDROGEN; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, PROGESTERONE; SOY FOODS; STILBENES; TRANSCRIPTIONAL ACTIVATION; TRIFOLIUM;

EID: 73349141384     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31819c146c     Document Type: Article

References (38)

1. Pinkerton JV, Santen R. Use of alternatives to estrogen, for treatment of menopause. Minerva Endocrinol 2002;27:21-41.
2. Geller S, Studee L. Soy and red clover for mid-life and aging. Climacteric 2006;9:245-263. (Pubitemid 44147845)
3. D'Anna R, Cannata ML, Atteritano M, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebocontrolled study. Menopause 2007;14:648-655.
4. Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 2001;8:259-265. (Pubitemid 32645959)
5. Dornstauder E, Jisa E, Unterrieder I, Krenn L, Kubelka W, Jungbauer A. Estrogenic activity of two standardized red clover extracts (Menoflavon®) intended for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2001; 78: 67-75. (Pubitemid 32786788)
6. Setchell KDR, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001; 131: 1362S-1375S. (Pubitemid 32268489)
7. Clarke DB, Bailey V, Lloyd AS. Determination of phytoestrogens in dietary supplements by LC-MS/MS. Food Addit Contam 2008; 25: 534-547. (Pubitemid 351910955)
8. Morito K, Aomori T, Hirose T, et al. Interaction of phytoestrogens with, estrogen receptors α and ß (II). Biol Pharm Bull 2002; 25: 48-52.
9. Morito K, Hirose T, Kinjo J, et al. Interaction of phytoestrogens with estrogen receptors α and ß. Biol Pharm Bull 2001; 24: 351-356.
10. Rosenberg Zand RS, Jenkins DJA, Diamandis EP. Steroid hormone activity of flavonoids and related compounds. Breast Cancer Res Treat 2000; 62: 35-49. (Pubitemid 30609562)
11. Wang SWJ, Chen Y, Joseph T, Hu M. Variable isoflavone content of red clover products affects intestinal disposition of biochanin A, formononetin, genistein and daidzein. J Altern Complement Med 2008; 14: 287-297.
12. Pfitscher A, Reiter E, Jungbauer A. Receptor binding and transactivation activities of red clover isoflavones and their metabolites. J Steroid Biochem Mol Biol 2008; 112: 87-94.
13. Herath W, Mikell JR, Hale AL, Ferreira D, Khan IA. Microbial metabolism. Part 6. Metabolites of 3- and 7-hydroxyflavones. Chem Pharm Bull 2006; 54: 320-324.
14. Kinjo J, Tsuchihashi R, Morito K, et al. Interactions of phytoestrogens with estrogen receptors α and ß (III). Estrogenic activities of soy isoflavone aglycones and their metabolites isolated from human urine. Biol Pharmaceutical Bull 2004; 27: 185-188. (Pubitemid 41694695)
15. Tsuchihashi R, Okawa M, Nohara T, Okabe H, Kinjo J. Soy isoflavone metabolites isolated from human urine. Nat Med 200458: 71-75. (Pubitemid 38856208)
16. Tsuchihashi R, Sakamoto S, Kodera M, Nohara T, Kinjo J. Microbial metabolism of soy isoflavones by human intestinal bacterial strains. Nat Med (Tokyo) 2008; 62: 456-460
17. Beck V, Rohr U, Jungbauer A. Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? J Steroid Biochem Mol Biol 2005; 94: 499-518. (Pubitemid 40616410)
18. Beck V, Unterrieder E, Krenn L, Kubelka W, Jungbauer A. Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2003; 84: 259-268 (Pubitemid 36514843)
19. Chen JJ, Chang HC, By modulating androgen, receptor coactivators, daidzein may act as a phytoandrogen. Prostate 2007; 67: 457-462.
20. Zava DT, Dollbaum CM, Blen M. Estrogen and progestin bioactivity of foods, herbs and spices. Exp Biol Med 1998; 217: 369-378. (Pubitemid 28130688)
21. Ricketts ML, Moore DD, Banz WJ, Mezei O, Shay NF. Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J Nutr Biochem 2005; 16: 321-330. (Pubitemid 40776040)
22. Shen P, Liu MH, Ng TY, Chan. YH, Yong EL. Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARα, PPARγ and adipocyte differentiation in vitro. J Nutr 2006; 136: 899-905.
23. Mueller M, Jungbauer A. Red clover extract-a putative source for simultaneous treatment of menopausal disorders and metabolic syndrome. Menopause 2008; 15: 1120-1131.
24. Medjakovic S, Jungbauer A. Red clover isoflavones biochanin A and formononetin are potent ligands of the human aryl hydrocarbon receptor. J Steroid Biochem Mol Biol 2008; 108: 171-177. (Pubitemid 351173832)
25. Harrington WW, Britt CS, Wilson. JG, et al. The effect of PPARα, PPARδ, PPARγ and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR/J mice. PPAR Res 2007. doi: 10.1155/2007/97125.
26. Wang YX, Lee CH, Tiep S, et al. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 2003; 113: 159-170. (Pubitemid 36514968)
27. Kharat I, Saatcioglu F. Antiestrogenic effects of 2,3,7,8- tetrachlorodibenzo-p-dioxin are mediated by direct transcriptional interference with the liganded estrogen, receptor: cross-talk between aryl hydrocarbon- and estrogen-mediated signaling. J Biol Chem 1996; 271: 10533-10537. (Pubitemid 26145787)
28. Wormke M, Castro-Rivera E, Chen I, Safe S. Estrogen and aryl hydrocarbon receptor expression and crosstalk, in human Ishikawa endometrial cancer cells. J Steroid Biochem Mol Biol 2000; 72: 197-207. (Pubitemid 30261524)
29. Freyberger A, Ahr HJ, Development and standardization of a simple binding assay for the detection, of compounds with affinity for the androgen receptor. Toxicology 2004; 195: 113-126. (Pubitemid 38125113)
30. Lyttle CR, Damian-Matsumura P, Juul H, Butt TR. Human estrogen receptor regulation in a yeast model system and studies on receptor agonists and antagonists. J Steroid Biochem Mol Biol 1992; 42: 677-685.
31. Staels B, Koenig W, Habib A, et al. Activation of human aortic smoothmuscle cells is inhibited by PPARα but not by PPARγ activators. Nature 1998; 393: 790-793. (Pubitemid 28299490)
32. Plísková M, Vondrácek J, Kren V, et al. Effects of Silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology 2005; 215: 80-89. (Pubitemid 41430276)
33. Harris DM, Besselink E, Henning SM, Go VLW, Heber D. Phytoestrogens induce differential estrogen receptor α- or ß-mediated responses in transfected breast cancer cells. Exp Biol Med 2005; 230: 558-568. (Pubitemid 41233155)
34. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor α (ER-α) and ER-ß in human cells. Toxicol Sci 2004; 80: 14-25. (Pubitemid 38967392)
35. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor ß acts as a dominant regulator of estrogen signaling. Oncogene 2000; 19: 4970-4978. (Pubitemid 30808362)
36. Covaleda AMS, Van den. Berg H, Vervoort J, et al. Influence of cellular ER-α/ER-ß ratio on the ER-a-agonist induced proliferation of human T47D breast cancer cells. Toxicol SCi 2008; 105: 303-311.
37. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003; 63: 1373-1405. (Pubitemid 36776093)
38. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288. (Pubitemid 32109807)